Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J, Willcox N
Division of Immunobiology, The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Herts, UK.
Immunology. 1999 Jul;97(3):526-32. doi: 10.1046/j.1365-2567.1999.00806.x.
There is increasing evidence that spontaneous anticytokine autoantibodies are associated with chronic infections and autoimmune diseases. We report the sporadic occurrence in autoimmune diseases of such autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine involved in inflammation and the regulation of proliferation, differentiation and function of granulocytic and monocytic cell lineages. In 41 of 425 patients tested, we found low to moderate levels of autoantibodies binding to GM-CSF in serum or plasma. These were most prevalent in patients with myasthenia gravis (MG). However, neutralizing autoantibodies against GM-CSF were very rare, being found in only three patients. Two had autoimmune MG, one with thymoma (Patient A) and the other (Patient B) with 'seronegative' MG, i.e. without the antiacetylcholine receptor autoantibodies characteristic of most MG patients, and a third (Patient D) had multiple sclerosis. Only very limited amounts of Patient A and Patient D serum/plasma were available for analysis and therefore further studies were carried out on the more plentiful samples from Patient B. The anti-GM-CSF autoantibodies of Patient B were predominantly polyclonal immunoglobulin G and strongly neutralized recombinant human (rh) GM-CSF derived from different expression systems. They had similar immunological and immunochemical characteristics to anti-GM-CSF antibodies that developed in immunocompetent colorectal carcinoma patients following (rh)GM-CSF therapy. In serial samples from Patient B, the anti-GM-CSF autoantibodies were undetectable from diagnosis at age 8 years until at least age 13, but then developed spontaneously during (temporary) withdrawal of immunosuppressive treatment. Their neutralizing activity has persisted since their first detection at age 15 years 1 month, and was at its highest level recently at age 17 years 7 months. There was no obvious association with other autoimmune phenomena, nor were any haematological deficiencies overtly manifested, suggesting that any loss of GM-CSF function may have been compensated for by other cytokines.
越来越多的证据表明,自发性抗细胞因子自身抗体与慢性感染和自身免疫性疾病有关。我们报告了自身免疫性疾病中偶发的针对粒细胞巨噬细胞集落刺激因子(GM-CSF)的自身抗体,GM-CSF是一种参与炎症以及粒细胞和单核细胞谱系增殖、分化和功能调节的细胞因子。在425名接受检测的患者中,有41名患者的血清或血浆中存在低至中等水平的与GM-CSF结合的自身抗体。这些自身抗体在重症肌无力(MG)患者中最为普遍。然而,针对GM-CSF的中和性自身抗体非常罕见,仅在三名患者中发现。两名患者患有自身免疫性MG,一名患有胸腺瘤(患者A),另一名(患者B)患有“血清阴性”MG,即没有大多数MG患者特有的抗乙酰胆碱受体自身抗体,第三名(患者D)患有多发性硬化症。由于仅获得了非常有限量的患者A和患者D的血清/血浆用于分析,因此对来自患者B的更丰富样本进行了进一步研究。患者B的抗GM-CSF自身抗体主要是多克隆免疫球蛋白G,并且强烈中和来自不同表达系统的重组人(rh)GM-CSF。它们具有与免疫功能正常的结直肠癌患者在接受(rh)GM-CSF治疗后产生的抗GM-CSF抗体相似的免疫学和免疫化学特征。在患者B的系列样本中,从8岁诊断时起直至至少13岁,均未检测到抗GM-CSF自身抗体,但在(暂时)停用免疫抑制治疗期间自发产生。自15岁1个月首次检测到以来,它们的中和活性一直持续存在,最近在17岁7个月时达到最高水平。与其他自身免疫现象没有明显关联,也没有明显表现出任何血液学缺陷,这表明GM-CSF功能的任何丧失可能已被其他细胞因子所补偿。